Ambria Dermatology develops a patented delivery platform for improving dermal delivery of topically applied pharmaceuticals.
Encubator Exit Company from 2001.
The company was an Encubator Start-up Project in 2001 and as of October 2009, operates as a subsidiary of Natumin Pharma AB.
The technology is a patented delivery platform, based on pentane-1,5-diol, for improving dermal delivery of topically applied pharmaceuticals. Ambria’s intellectual property position is built on several patent families, in-licensed rights and product trademarks.
Ambria currently has several products under development, primarily pre-clinical, where two products have undergone early clinical testing.
The technology will initially be deployed in products addressing significant unmet medical needs in large patient groups such as the treatment of multi-resistant bacteria, infected atopic dermatitis, psoriasis and exzema. Another potential use of the platform is the cosmetic market for treating dry skin and dandruff.
Ambria Dermatology is an Encubator Exit Company from CSE class of 2001.
Pharmaceuticals
+46 36 - 39 65 50
Kullagatan 8, Helsingborg
